00:19:19 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-25 Bokslutskommuniké 2024
2024-10-31 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-06-12 X-dag ordinarie utdelning DIABIO 0.00 SEK
2024-06-11 Årsstämma 2024
2024-05-31 Kvartalsrapport 2024-Q1
2024-02-28 Bokslutskommuniké 2023
2023-10-31 Kvartalsrapport 2023-Q3
2023-09-22 Extra Bolagsstämma 2023
2023-08-22 Kvartalsrapport 2023-Q2
2023-05-12 X-dag ordinarie utdelning DIABIO 0.00 SEK
2023-05-11 Kvartalsrapport 2023-Q1
2023-05-11 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-23 Extra Bolagsstämma 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-12 X-dag ordinarie utdelning DIABIO 0.00 SEK
2022-05-11 Årsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-10-29 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Diagonal Bio är verksamt inom bioteknik. Bolaget utvecklar en plattform under namnet Panviral för att detektera och diagnostisera små sektioner av patogengenom, som exempelvis virus, bakterier och svampar. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Sverige med huvudkontor i Lund.
2024-05-23 14:47:35

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has appointed Fata Mrsic as the new Chief Financial Officer (CFO). Fata will assume the position on June 14, 2024, and be part of the Management Team.

Fata Mrsic has extensive financial and accounting experience. She has held Business Controller and Accounting positions at several companies in the past 15 years, some with global presence. Fata has a Diploma in Business Controlling from the University of Lund.  

"We welcome Fata Mrsic as our new CFO. Fata knows our company well already since she started as Business Controller in Diagonal Bio in March this year. Her vast experience within the field will contribute highly to the operational and strategic work at Diagonal Bio," comments Karin Wehlin, CEO at Diagonal Bio.

"I am happy to continue my journey within Diagonal Bio. Our innovative way to speed up the testing process for different viruses and to contribute to better health in animals and humans is something that I am very passionate about. It's an exciting time to be part of the company, now that we have LAMPlify®️ in Pilot tests at veterinarians. I look forward to our journey," says Fata Mrsic.

For more information about the Company, please contact:

Karin Wehlin, CEO
Phone: +46 (0)70305 24 88
E-mail: kw@diagonalbio.com
www.diagonalbio.com

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionizing global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.